Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Use Hep-C: HCV+ Kidney Transplant to HCV- Recipients
NCT03801707Phase 3Completed
- Sponsor
- The Ohio State University
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of sofosbuvir, velpatasvir, glecaprevir, pibrentasvir in hepatitis C (HCV), sponsored by The Ohio State University. Started Mar 2019; status: completed.
02
Drugs
sofosbuvirvelpatasvirglecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03801707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801707.